FDA approves new treatment for bladder cancer
On May 18, the U.S. the Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) to treat urothelial carcinoma. Read more
Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.